Navigation Links
Quark Announces Dosing of the First Patient in Phase I Clinical Trial of its Ocular Neuroprotective Agent, QPI-1007
Date:3/1/2010

FREMONT, Calif., March 1 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today the dosing of the first patient in a Phase I study of the investigational neuroprotective agent, QPI-1007.  This drug candidate, having a proprietary siRNA structure, is being developed for the treatment of non-arteritic anterior ischemic optic neuropathy (NAION).  The current trial represents the seventh clinical study of Quark synthetic siRNAs.  QPI-1007 has been evaluated in several preclinical models of ocular neuroprotection, and has been shown in these models to protect retinal ganglion cells from injury-induced apoptosis.

The study is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug will be given to all patients who participate.  This study will determine whether QPI-1007 is safe when it is injected into the eye and will also reveal if there are any side effects of the drug and how long it takes for the body to clear the drug.  In addition, the study will examine the biological activity of the drug in NAION patients.  The study will enroll patients in two strata, and is being conducted in the U.S. and Israel.  Stratum I will enroll legally blind patients, while stratum II will enroll patients with recent onset of NAION.


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals siRNA Drugs In Multiple Fully Enrolled Clinical Trials
2. Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
3. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
4. Quark Pharmaceuticals Presents at Asia TIDES Conference
5. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
6. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
7. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
10. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
11. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 As health officials across the Midwest warn against ... in Michigan will offer free diagnostic ... Meijer pharmacists to administer tests and, in some cases, fill ... participating in the study. The Grand ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2
(Date:4/16/2014)... marvel of the embryo. It begins as a glob of ... to become the cells of our lungs, muscles, nerves and ... in a feat of reverse tissue engineering, Stanford University researchers ... embryonic cells to proliferate and transform into all of the ...
(Date:4/16/2014)... Therapeutics, Inc. (NASDAQ: CLDX) announced today that final data ... tumors, including long-term patient follow-up, have been published in ... The data demonstrate robust antibody and T cell responses ... advanced cancers and suggest that CDX-1401 may predispose patients ...
(Date:4/16/2014)... DOWNERS GROVE, Ill. April 16, 2014 According ... surveillance colonoscopy in average-risk patients with one to two ... 90 percent of cases. This may be an appropriate ... endoscopic database study to quantify adherence to guidelines for ...
(Date:4/15/2014)... Cases of diabetes and pre-diabetes in the United States have ... Hopkins Bloomberg School of Public Health, with obesity apparently to ... burden of the disease has not hit all groups equally, ... elderly. , According to new research reported in the April ...
(Date:4/15/2014)... solved a decades-old medical mystery and in the process have ... which kill about 1.5 million people a year. The researchers say ... drug that has been in use for more than 50 years ... as it is to the microbes it attacks. , A ...
Breaking Medicine News(10 mins):Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3
... , WEDNESDAY, Jan. 4 (HealthDay News) -- Remember those ... but you took the plunge and whizzed downward. Next, ... and hanging by your knees at the pinnacle. ... sliding boards, safer plastic climbers and fence-protected platforms are ...
... CareFirst BlueCross BlueShield (CareFirst) today announced that it has ... make available the ACP,s Medical Home Builder 2.0 ... (PCMH) practices. The ACP developed MHB 2.0 as ... care, organization, and workflow. CareFirst is making the ...
... By Serena Gordon HealthDay Reporter , TUESDAY, ... in the United States are far more likely to be ... 16 other countries, a new study indicates. Researchers suspect ... days in the United States compared with at least six ...
... -- The current issue of Medical Acupuncture , ... explores how the U.S. military is incorporating medical acupuncture ... serving in the war zones and the efforts underway ... available online at http://www.liebertpub.com/acu . "The use ...
... pharmaceutical industry continues to globalize, the challenges of securing ... as well as the consequences of lapses in security ... encourage comprehensive public standards across the pharmaceutical industry, the ... recommended best practices that will help ensure that medicines ...
... of two substances in licorice used extensively in Chinese ... tooth decay and gum disease, the leading causes of tooth ... Journal of Natural Products , they say that these ... decay and gum disease. Stefan Gafner and colleagues ...
Cached Medicine News:Health News:'Safety-First' Playgrounds Linked to Bored, Inactive Kids: Study 2Health News:'Safety-First' Playgrounds Linked to Bored, Inactive Kids: Study 3Health News:CareFirst BCBS and ACP offer new tool to advance development of patient-centered medical homes 2Health News:CareFirst BCBS and ACP offer new tool to advance development of patient-centered medical homes 3Health News:U.S. Heart Attack Patients Readmitted Most Often: Study 2Health News:U.S. Heart Attack Patients Readmitted Most Often: Study 3Health News:Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity 2Health News:Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity 3Health News:Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity 4
... seats and large backrests with lumbar support ... and casters and glides. • Choose the ... variety of environments including: industry, education, laboratory, ... office. • With cast aluminum base • ...
... chairs with concave seats and large ... options like seats, backrests, armrests, and ... BE Series for top performance in ... education, laboratory, clean room, static control, ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With cast ...
Medicine Products: